In the second part of our series from the 'Patient Experience: Empathy and Innovation' Digital Summit, we look at what COVID-19 can teach us about designing truly value-based healthcare.
AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio